The BDKRB1 agonist markedly reduces clinical symptoms of experimental autoimmune encephalomyelitis in mice, whereas its antagonist leads to accelerated disease onset and greater severity of the disease31. This evidence concerns the gene BDKRB1 and experimental autoimmune encephalomyelitis.